The U.S. Supreme Court declined Dec. 9 to review an unpublished decision by the U.S. Court of Appeals for the Ninth Circuit that upheld the exclusion of evidence in a suit by a woman alleging Lupron manufacturers TAP Pharmaceutical Products Inc. and Abbott Laboratories failed to adequately warn about risks associated with the drug (Klein v. TAP Pharm. Prod. Inc., U.S., No. 13-542).
Karin Klein was prescribed Lupron injections from August 2005 until January 2006 to treat pain associated with endometriosis. She alleged the drug caused her to develop thyroid disease and bone density loss.
A jury in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.